GLP-1R agonists also showed beneficial effects in other neurodegenerative diseases such as Friedreich’s ataxia, Parkinson’s and Alzheimer’s disease, where they reduce neuronal degeneration and loss, alleviate oxidative stress, attenuate behavioural deficits, decrease neuroinflammation or reduce pathological protein aggregation, among others [19, 36]. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.